Clock drawing test: comparison between the Pfizer and the Shulman systems
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Dementia & Neuropsychologia |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642021000400480 |
Resumo: | ABSTRACT Cognitive decline can be screened by the clock drawing test (CDT), which has several versions. Objective: This survey aimed to analyze the correlation between two simple methods for scoring the CDT. Methods: This cross-sectional study was nested in the Elo-Creati cohort from Passo Fundo, Brazil and comprised 404 subjects. Two raters underwent previous training and scored the subjects’ CDT according to both the Pfizer and Shulman systems. The inter-observer and intra-observer concordance within each method was analyzed with the Spearman’s rank correlation coefficient, as well as the concordance of the scores between the two methods. Age and scholarity were also correlated with the scores. Results: Most of the participants were women (93.8%) and Caucasian (84.6%), with a mean age of 66.9 (±7.8) years and a scholarity of 10.9 years (±5.6). There was significant inter-observer (Pfizer: r=0.739, p£0.001; Shulman: r=0.727, p£0.001) and intra-observer correlation (Pfizer: rater 1, r=0.628, p≤0.001; rater 2, r=0.821, p≤0.001; Shulman: rater 1, r=0.843, p≤0.001; rater 2: r=0.819; p≤0.001). Intra-observer correlation was also observed comparing Pfizer and Shulman methods (rater 1: r=0.744; p≤0.001; rater 2: r=0.702; p≤0.001). There was weak correlation of the scores with scholarity (Pfizer: r=0.283, p£0.001; Shulman: r=0.244, p£0.001) and age (Pfizer: r=-0.174, p£0.001; Shulman: r=-0.170, p£0.001). More participants were classified with decreased cognition through the Pfizer system (rater 1: 44.3 vs. 26.5%; rater 2: 42.1 vs. 16.3%; p≤0.001). Conclusions: For this population, our results suggest that the Pfizer system of scoring CDT is more suitable for screening cognitive decline. |
id |
ANCC-1_9edb15ea9197e66f3997db8eae14b726 |
---|---|
oai_identifier_str |
oai:scielo:S1980-57642021000400480 |
network_acronym_str |
ANCC-1 |
network_name_str |
Dementia & Neuropsychologia |
repository_id_str |
|
spelling |
Clock drawing test: comparison between the Pfizer and the Shulman systemscognitive declinescreeningclock drawing testcorrelationABSTRACT Cognitive decline can be screened by the clock drawing test (CDT), which has several versions. Objective: This survey aimed to analyze the correlation between two simple methods for scoring the CDT. Methods: This cross-sectional study was nested in the Elo-Creati cohort from Passo Fundo, Brazil and comprised 404 subjects. Two raters underwent previous training and scored the subjects’ CDT according to both the Pfizer and Shulman systems. The inter-observer and intra-observer concordance within each method was analyzed with the Spearman’s rank correlation coefficient, as well as the concordance of the scores between the two methods. Age and scholarity were also correlated with the scores. Results: Most of the participants were women (93.8%) and Caucasian (84.6%), with a mean age of 66.9 (±7.8) years and a scholarity of 10.9 years (±5.6). There was significant inter-observer (Pfizer: r=0.739, p£0.001; Shulman: r=0.727, p£0.001) and intra-observer correlation (Pfizer: rater 1, r=0.628, p≤0.001; rater 2, r=0.821, p≤0.001; Shulman: rater 1, r=0.843, p≤0.001; rater 2: r=0.819; p≤0.001). Intra-observer correlation was also observed comparing Pfizer and Shulman methods (rater 1: r=0.744; p≤0.001; rater 2: r=0.702; p≤0.001). There was weak correlation of the scores with scholarity (Pfizer: r=0.283, p£0.001; Shulman: r=0.244, p£0.001) and age (Pfizer: r=-0.174, p£0.001; Shulman: r=-0.170, p£0.001). More participants were classified with decreased cognition through the Pfizer system (rater 1: 44.3 vs. 26.5%; rater 2: 42.1 vs. 16.3%; p≤0.001). Conclusions: For this population, our results suggest that the Pfizer system of scoring CDT is more suitable for screening cognitive decline.Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642021000400480Dementia & Neuropsychologia v.15 n.4 2021reponame:Dementia & Neuropsychologiainstname:Associação de Neurologia Cognitiva e do Comportamento (ANCC)instacron:ANCC10.1590/1980-57642021dn15-040009info:eu-repo/semantics/openAccessGraeff,Daniela BertolLui,Jéssica MaldanerZucco,Nathália Dal PráAlves,Ana Luisa Sant’AnnaForcelini,Cassiano MateusDalmolin,Bernadete Mariaeng2021-12-01T00:00:00Zoai:scielo:S1980-57642021000400480Revistahttp://www.demneuropsy.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||demneuropsy@uol.com.br1980-57641980-5764opendoar:2021-12-01T00:00Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC)false |
dc.title.none.fl_str_mv |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
title |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
spellingShingle |
Clock drawing test: comparison between the Pfizer and the Shulman systems Graeff,Daniela Bertol cognitive decline screening clock drawing test correlation |
title_short |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
title_full |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
title_fullStr |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
title_full_unstemmed |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
title_sort |
Clock drawing test: comparison between the Pfizer and the Shulman systems |
author |
Graeff,Daniela Bertol |
author_facet |
Graeff,Daniela Bertol Lui,Jéssica Maldaner Zucco,Nathália Dal Prá Alves,Ana Luisa Sant’Anna Forcelini,Cassiano Mateus Dalmolin,Bernadete Maria |
author_role |
author |
author2 |
Lui,Jéssica Maldaner Zucco,Nathália Dal Prá Alves,Ana Luisa Sant’Anna Forcelini,Cassiano Mateus Dalmolin,Bernadete Maria |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Graeff,Daniela Bertol Lui,Jéssica Maldaner Zucco,Nathália Dal Prá Alves,Ana Luisa Sant’Anna Forcelini,Cassiano Mateus Dalmolin,Bernadete Maria |
dc.subject.por.fl_str_mv |
cognitive decline screening clock drawing test correlation |
topic |
cognitive decline screening clock drawing test correlation |
description |
ABSTRACT Cognitive decline can be screened by the clock drawing test (CDT), which has several versions. Objective: This survey aimed to analyze the correlation between two simple methods for scoring the CDT. Methods: This cross-sectional study was nested in the Elo-Creati cohort from Passo Fundo, Brazil and comprised 404 subjects. Two raters underwent previous training and scored the subjects’ CDT according to both the Pfizer and Shulman systems. The inter-observer and intra-observer concordance within each method was analyzed with the Spearman’s rank correlation coefficient, as well as the concordance of the scores between the two methods. Age and scholarity were also correlated with the scores. Results: Most of the participants were women (93.8%) and Caucasian (84.6%), with a mean age of 66.9 (±7.8) years and a scholarity of 10.9 years (±5.6). There was significant inter-observer (Pfizer: r=0.739, p£0.001; Shulman: r=0.727, p£0.001) and intra-observer correlation (Pfizer: rater 1, r=0.628, p≤0.001; rater 2, r=0.821, p≤0.001; Shulman: rater 1, r=0.843, p≤0.001; rater 2: r=0.819; p≤0.001). Intra-observer correlation was also observed comparing Pfizer and Shulman methods (rater 1: r=0.744; p≤0.001; rater 2: r=0.702; p≤0.001). There was weak correlation of the scores with scholarity (Pfizer: r=0.283, p£0.001; Shulman: r=0.244, p£0.001) and age (Pfizer: r=-0.174, p£0.001; Shulman: r=-0.170, p£0.001). More participants were classified with decreased cognition through the Pfizer system (rater 1: 44.3 vs. 26.5%; rater 2: 42.1 vs. 16.3%; p≤0.001). Conclusions: For this population, our results suggest that the Pfizer system of scoring CDT is more suitable for screening cognitive decline. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642021000400480 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642021000400480 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1980-57642021dn15-040009 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento |
dc.source.none.fl_str_mv |
Dementia & Neuropsychologia v.15 n.4 2021 reponame:Dementia & Neuropsychologia instname:Associação de Neurologia Cognitiva e do Comportamento (ANCC) instacron:ANCC |
instname_str |
Associação de Neurologia Cognitiva e do Comportamento (ANCC) |
instacron_str |
ANCC |
institution |
ANCC |
reponame_str |
Dementia & Neuropsychologia |
collection |
Dementia & Neuropsychologia |
repository.name.fl_str_mv |
Dementia & Neuropsychologia - Associação de Neurologia Cognitiva e do Comportamento (ANCC) |
repository.mail.fl_str_mv |
||demneuropsy@uol.com.br |
_version_ |
1754212932816732160 |